We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
-16.28%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
-$54.8M
Cap. Flow
+$19.9M
Cap. Flow %
7.6%
Top 10 Hldgs %
88.78%
Holding
24
New
3
Increased
1
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$98.9M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.5M
3
RDUS
Radius Health, Inc.
RDUS
+$335K
4
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$29.5K

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$30.1M
2
ZGNX
Zogenix, Inc.
ZGNX
+$17.3M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$10.8M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$10.6M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$6.1B
$90M 34.31%
+1,786,431
New +$98.9M
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$29.7M 11.33%
712,903
-250,000
-26% -$10.6M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.6B
$22.6M 8.61%
234,591
-269,619
-53% -$30.1M
SWAV
4
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$19.3M 7.37%
646,427
-254,829
-28% -$10.8M
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$18.8M 7.15%
2,252,460
– –
AXSM icon
6
Axsome Therapeutics
AXSM
$12.4B
$18.1M 6.89%
892,946
– –
RARX
7
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$16M 6.1%
677,164
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.38B
$8.24M 3.14%
2,874,602
– –
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.71B
$5.13M 1.95%
426,781
– –
SPRO icon
10
Spero Therapeutics
SPRO
$67.2M
$5.03M 1.92%
474,015
– –
CNST
11
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.69M 1.79%
726,677
– –
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$4.85B
$4.6M 1.75%
540,461
-68,620
-11% -$758K
LJPC
13
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.56M 1.74%
518,102
– –
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
$4.37M 1.67%
376,889
– –
TCDA
15
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.67M 1.4%
118,886
-309,845
-72% -$10.4M
MIST icon
16
Milestone Pharmaceuticals
MIST
$149M
$2.77M 1.06%
148,560
– –
MRNS
17
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.29M 0.87%
371,669
+185,700
+100% +$1.5M
BLPH
18
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2M 0.76%
276,625
– –
RDUS
19
DELISTED
Radius Health, Inc.
RDUS
$352K 0.13%
+13,667
New +$335K
KA
20
DELISTED
Kineta, Inc. Common Stock
KA
$110K 0.04%
934
– –
PRVL
21
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$32K 0.01%
+2,604
New +$29.5K
MTVA
22
MetaVia Inc
MTVA
$7.8M
– –
-7
Closed -$382K
KDMN
23
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-249,463
Closed -$514K
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
– –
-362,010
Closed -$17.3M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q3 2019 Portfolio in Review

As of Q3 2019, VHCP Management II held 24 positions worth $262M, down 17% from $317M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

VHCP Management II deployed $19.9M of net new capital in Q3 2019, opening 3 new positions and adding to 1 existing holding. Its largest new stake was 10x Genomics: 1,786,431 shares worth $90M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $30.1M trimmed.

  • VHCP Management II's largest Q3 2019 buy was 10x Genomics: 1,786,431 shares worth $90M.
  • VHCP Management II added most to Marinus Pharmaceuticals, Inc in Q3 2019, an estimated $1.5M increase.
  • VHCP Management II's biggest Q3 2019 reduction was Ascendis Pharma A/S, cutting an estimated $30.1M.
  • VHCP Management II fully exited Zogenix, Inc. in Q3 2019, selling an estimated $17.3M.
  • VHCP Management II's ten largest holdings make up 89% of its $262M portfolio in Q3 2019.
  • VHCP Management II opened 3 new positions and closed 3 in Q3 2019.
  • VHCP Management II's portfolio value fell 17% quarter-over-quarter to $262M.

Based on VHCP Management II's 13F filing for Q3 2019, filed 13 Nov 2019.